BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 26, 2013
View Archived Issues
MIR146A gene polymorphisms linked to atrial fibrillation prognosis
Read More
Presentation of the data from clinical trials of dulaglutide
Read More
Development of an antimalaria vaccine that targets disease transmission
Read More
Data from the clinical evaluation of a prophylactic therapy for patients with hemophilia B
Read More
Teva enters collaboration with Israeli academic institutions in neurodegenerative disease
Read More
North Carolina State University discloses new agents for bacterial infections
Read More
Researchers at Roche present novel tyrosine-protein kinase inhibitors
Read More
Teva and Lonza decide to discontinue joint venture in biosimilars
Read More
Roche synthesizes novel TAAR1 ligands
Read More
Candesartan is as effective as propranolol for preventing migraine
Read More
Invion begins phase II INV-102 trial
Read More
FDA approves Fetzima for major depressive disorder in adults
Read More
CHMP confirms Xeljanz recommendation
Read More
Thrombomodulin downregulated thrombin generation mediators/markers in sepsis-associated coagulopathy
Read More
New FSH receptor agonists disclosed by Merck KGaA for female infertility
Read More
AstraZeneca and Bristol-Myers Squibb resubmit NDA for dapagliflozin
Read More
Curis commences phase I study of CUDC-427 in advanced malignancies
Read More
Diazyme obtains 510(k) clearance from FDA to market its myoglobin assay
Read More
Jiangsu Hengrui Medicine synthesizes novel GPR40 agonists
Read More
Kyowa Hakko Kirin Korea begins patient recruitment in phase I/II study of BIW-8962 in lung cancer
Read More
Researchers at X-Rx/X-Chem report new tyrosine-protein kinase BTK inhibitors
Read More
Phase III orteronel study in metastatic castration-resistant prostate cancer unblinded
Read More
IND approved for oncolytic agent 3-bromopyruvate
Read More
InSite Vision reports topline results from DOUBle phase III study in blepharitis
Read More
Tesaro begins phase III trial of niraparib for treatment of ovarian cancer
Read More